Inflammatory mechanisms in tendinopathy - towards translation

Nature Reviews Rheumatology

Volumn 13, Issue 2, 2017, Pages 110-122

  Millar, Neal L ^a   Murrell, George A C ^b   Mcinnes, Iain B ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ST GEORGE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANAKINRA; CYTOKINE; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; LIPOXIN; NITRIC OXIDE; PROSTAGLANDIN;

CD4+ T LYMPHOCYTE; CLINICAL EXAMINATION; CLINICAL FEATURE; ENTHESITIS; ENTHESOPATHY; EXERCISE TOLERANCE; EXTRACELLULAR MATRIX; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; ISOMETRIC EXERCISE; MECHANICAL STRESS; MOLECULAR MECHANICS; NATURAL KILLER CELL; NONHUMAN; OSTEOARTHRITIS; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSIOTHERAPY; REVIEW; SOCIOECONOMICS; T LYMPHOCYTE; TENDINITIS; COMPLICATION; PHYSIOLOGY; TENDINOPATHY; TENDON; TRANSLATIONAL RESEARCH;

CYTOKINES; HUMANS; INFLAMMATION; TENDINOPATHY; TENDONS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85010876970     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2016.213     Document Type: Review

References (164)

1. Riley G. Chronic tendon pathology: molecular basis and therapeutic implications. Expert Rev. Mol. Med. 7, 1-25 (2005).
2. Riley G. Tendinopathy -from basic science to treatment. Nat. Clin. Pract. Rheumatol. 4, 82-89 (2008).
3. McGonagle D, Marzo-Ortega H, Benjamin M, & Emery P. Report on the Second International Enthesitis Workshop. Arthritis Rheum. 48, 896-905 (2003).
4. Khan K, Cook J, Kannus P, Maffulli N, & Bonar S. Time to abandon the "tendinitis" myth: painful, overuse tendon conditions have a non-inflammatory pathology. BMJ 324, 626 (2002).
5. Khan K. M, Cook J. L, Taunton J. E, & Bonar F. Overuse tendinosis, not tendinitis. Phys. Sportsmed. 28, 38-48 (2000).
6. Felson D. T, et al. Risk factors for incident radiographic knee osteoarthritis in the elderly: the Framingham Study. Arthritis Rheum. 40, 728-733 (1997).
7. Pelletier J. P, Martel-Pelletier J, & Howell D. S. in Arthritis and Allied Conditions: a Textbook of Rheumatology 14th edn (eds Koopman W. J.) 2195-2245 (Lippincott Williams and Wilkins, 2000).
8. Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage 21, 16-21 (2013).
9. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier J. P, & Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat. Rev. Rheumatol. 7, 33-42 (2011).
10. Sokolove J, & Lepus C. M. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther. Adv. Musculoskelet. Dis. 5, 77-94 (2013).
11. Benjamin M, & McGonagle D. Basic concepts of enthesis biology and immunology. J. Rheumatol. Suppl. 83, 12-13 (2009).
12. Benjamin M, & McGonagle D. The enthesis organ concept and its relevance to the spondyloarthropathies. Adv. Exp. Med. Biol. 649, 57-70 (2009).
13. Sherlock J. P, et al. IL 23 induces spondyloarthropathy by acting on ROR-γ+CD3+CD4-CD8-entheseal resident T cells. Nat. Med. 18, 1069-1076 (2012).
14. Jacques P, et al. Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann. Rheum. Dis. 73, 437-445 (2014).
15. Xu Y, & Murrell G. A. The basic science of tendinopathy. Clin. Orthop. Relat. Res. 466, 1528-1538 (2008).
16. Abate M, et al. Pathogenesis of tendinopathies: inflammation or degeneration?. Arthritis Res. Ther. 11, 235 (2009).
17. Medzhitov R. Origin and physiological roles of inflammation. Nature 454, 428-435 (2008).
18. Dakin S. G, Dudhia J, & Smith R. K. Resolving an inflammatory concept: the importance of inflammation and resolution in tendinopathy. Vet. Immunol. Immunopathol. 158, 121-127 (2014).
19. Maffulli N, Khan K. M, & Puddu G. Overuse tendon conditions: time to change a confusing terminology. Arthroscopy 14, 840-843 (1998).
20. Couppe C, Svensson R. B, Silbernagel K. G, Langberg H, & Magnusson S. P. Eccentric or concentric exercises for the treatment of tendinopathies?. J. Orthop. Sports Phys. Ther. 45, 853-863 (2015).
21. Rio E, et al. Isometric exercise induces analgesia and reduces inhibition in patellar tendinopathy. Br. J. Sports Med. 49, 1277-1283 (2015).
22. Andres B. M, & Murrell G. A. Treatment of tendinopathy: what works, what does not, and what is on the horizon. Clin. Orthop. Relat. Res. 466, 1539-1554 (2008).
23. Alfredson H, & Cook J. A treatment algorithm for managing Achilles tendinopathy: new treatment options. Br. J. Sports Med. 41, 211-216 (2007).
24. Chan K. M, & Fu S. C. Anti-inflammatory management for tendon injuries -friends or foes?. Sports Med. Arthrosc. Rehabil. Ther. Technol. 1, 23 (2009).
25. Paoloni J, De Vos R. J, Hamilton B, Murrell G. A, & Orchard J. Platelet-rich plasma treatment for ligament and tendon injuries. Clin. J. Sport Med. 21, 37-45 (2011).
26. Krogh T. P, et al. Treatment of lateral epicondylitis with platelet-rich plasma, glucocorticoid, or saline: a randomized, double-blind, placebo-controlled trial. Am. J. Sports Med. 41, 625-635 (2013).
27. de Vos R. J, et al. Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA 303, 144-149 (2010).
28. Smith R. K. Mesenchymal stem cell therapy for equine tendinopathy. Disabil. Rehabil. 30, 1752-1758 (2008).
29. Cyranoski D. Stem cells boom in vet clinics. Nature 496, 148-149 (2013).
30. Bahr R, Fossan B, Loken S, & Engebretsen L. Surgical treatment compared with eccentric training for patellar tendinopathy (Jumper?s Knee). A randomized, controlled trial. J. Bone Joint Surg. Am. 88, 1689-1698 (2006).
31. Kirkendall D, & Garrett W. Function and biomechanics of tendons. Scand. J. Med. Sci. Sports 7, 62-66 (1997).
32. Maffulli N, & Benazzo F. Basic Science of Tendons. Sports Med. Arthrosc. Rev. 8, 1-5 (2000).
33. O?Brien M. Structure and metabolism of tendons. Scand. J. Med. Sci. Sports 7, 55-61 (1997).
34. Thorpe C. T, et al. Tendon overload results in alterations in cell shape and increased markers of inflammation and matrix degradation. Scand. J. Med. Sci. Sports 25, e381-e391 (2015).
35. Thorpe C. T, Riley G. P, Birch H. L, Clegg P. D, & Screen H. R. Effect of fatigue loading on structure and functional behaviour of fascicles from energy-storing tendons. Acta Biomater. 10, 3217-3224 (2014).
36. Khan K. M, Cook J. L, Bonar F, Harcourt P, & Astrom M. Histopathology of common tendinopathies. Update and implications for clinical management. Sports Med. 27, 393-408 (1999).
37. Kannus P, & Jozsa L. Histopathological changes preceding spontaneous rupture of a tendon. A controlled study of 891 patients. J. Bone Joint Surg. Am. 73, 1507-1525 (1991).
38. Kannus P, Jozsa L, & Jarvinen M. in Principles and Practice of Orthopaedic Sports Medicine (eds Garrett W. E. Jr, Speer K. P, & Kirkendall D. T.) 21-37 (Lippincott Williams and Wilkins, 2000).
39. Maffulli N, Barrass V, & Ewen S. W. Light microscopic histology of achilles tendon ruptures. A comparison with unruptured tendons. Am. J. Sports Med. 28, 857-863 (2000).
40. Maffulli N, Ewen S. W, Waterston S. W, Reaper J, & Barrass V. Tenocytes from ruptured and tendinopathic achilles tendons produce greater quantities of type III collagen than tenocytes from normal achilles tendons. An in vitro model of human tendon healing. Am. J. Sports Med. 28, 499-505 (2000).
41. Maeda E, Noguchi H, Tohyama H, Yasuda K, & Hayashi K. The tensile properties of collagen fascicles harvested from regenerated and residual tissues in the patellar tendon after removal of the central third. Biomed. Mater. Eng. 17, 77-85 (2007).
42. Arnoczky S. P, Lavagnino M, & Egerbacher M. The mechanobiological aetiopathogenesis of tendinopathy: is it the over-stimulation or the under-stimulation of tendon cells?. Int. J. Exp. Pathol. 88, 217-226 (2007).
43. Cook J. L, Feller J. A, Bonar S. F, & Khan K. M. Abnormal tenocyte morphology is more prevalent than collagen disruption in asymptomatic athletes? patellar tendons. J. Orthop. Res. 22, 334-338 (2004).
44. Jozsa L, & Kannus P. Histopathological findings in spontaneous tendon ruptures. Scand. J. Med. Sci. Sports 7, 113-118 (1997).
45. Pingel J, et al. 3D ultrastructure and collagen composition of healthy and overloaded human tendon: evidence of tenocyte and matrix buckling. J. Anat. 224, 548-555 (2014).
46. Khan K. M, Cook J. L, Maffulli N, & Kannus P. Where is the pain coming from in tendinopathy?. It may be biochemical, not only structural, in origin. Br. J. Sports Med. 34, 81-83 (2000).
47. De Jonge S, et al. Relationship between neovascularization and clinical severity in Achilles tendinopathy in 556 paired measurements. Scand. J. Med. Sci. Sports 24, 773-778 (2014).
48. Tol J. L, Spiezia F, & Maffulli N. Neovascularization in Achilles tendinopathy: have we been chasing a red herring?. Knee Surg. Sports Traumatol. Arthrosc. 20, 1891-1894 (2012).
49. Yuan J, Murrell G. A, Wei A. Q, & Wang M. X. Apoptosis in rotator cuff tendonopathy. J. Orthop. Res. 20, 1372-1379 (2002).
50. Arnoczky S. P, Tian T, Lavagnino M, & Gardner K. Ex vivo static tensile loading inhibits MMP 1 expression in rat tail tendon cells through a cytoskeletally based mechanotransduction mechanism. J. Orthop. Res. 22, 328-333 (2004).
51. Mokone G. G, Schwellnus M. P, Noakes T. D, & Collins M. The COL5A1 gene and Achilles tendon pathology. Scand. J. Med. Sci. Sports 16, 19-26 (2006).
52. Dean B. J, Franklin S. L, & Carr A. J. The peripheral neuronal phenotype is important in the pathogenesis of painful human tendinopathy: a systematic review. Clin. Orthop. Relat. Res. 471, 3036-3046 (2013).
53. Millar N. L, Wei A. Q, Molloy T. J, Bonar F, & Murrell G. A. Cytokines and apoptosis in supraspinatus tendinopathy. J. Bone Joint Surg. Br. 91, 417-424 (2009).
54. Del Buono A, Battery L, Denaro V, Maccauro G, & Maffulli N. Tendinopathy and inflammation: some truths. Int. J. Immunopathol. Pharmacol. 24, 45-50 (2011).
55. Sharma P, & Maffulli N. Tendon injury and tendinopathy: healing and repair. J. Bone Joint Surg. Am. 87, 187-202 (2005).
56. Cook J. L, & Purdam C. R. Is tendon pathology a continuum?. A pathology model to explain the clinical presentation of load-induced tendinopathy. Br. J. Sports Med. 43, 409-416 (2009).
57. Fu S. C, Rolf C, Cheuk Y. C, Lui P. P, & Chan K. M. Deciphering the pathogenesis of tendinopathy: a three-stages process. Sports Med. Arthrosc. Rehabil. Ther. Technol. 2, 30 (2010).
58. Alfredson H, Thorsen K, & Lorentzon R. In situ microdialysis in tendon tissue: high levels of glutamate, but not prostaglandin E2 in chronic Achilles tendon pain. Knee Surg. Sports Traumatol. Arthrosc. 7, 378-381 (1999).
59. Alfredson H, & Lorentzon R. Chronic tendon pain: no signs of chemical inflammation but high concentrations of the neurotransmitter glutamate. Implications for treatment?. Curr. Drug Targets 3, 43-54 (2002).
60. Khan K. M, Cook J. L, Kannus P, Maffulli N, & Bonar S. F. Time to abandon the "tendinitis" myth. BMJ 324, 626-627 (2002).
61. Millar N. L, Dean B. J, & Dakin S. G. Inflammation and the continuum model: time to acknowledge the molecular era of tendinopathy. Br. J. Sports Med. 50, 1486 (2016).
62. Blazina M. E, Kerlan R. K, Jobe F. W, Carter V. S, & Carlson G. J. Jumper?s knee. Orthop. Clin. North Am. 4, 665-678 (1973).
63. Battery L, & Maffulli N. Inflammation in overuse tendon injuries. Sports Med. Arthrosc. 19, 213-217 (2011).
64. Lories R. J, & McInnes I. B. Primed for inflammation: enthesis-resident T cells. Nat. Med. 18, 1018-1019 (2012).
65. Buckley C. D, Barone F, Nayar S, Benezech C, & Caamano J. Stromal cells in chronic inflammation and tertiary lymphoid organ formation. Annu. Rev. Immunol. 33, 715-745 (2015).
66. Iwamoto T, Okamoto H, Toyama Y, & Momohara S. Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients. FEBS J. 275, 4448-4455 (2008).
67. Croft A. P, et al. Rheumatoid synovial fibroblasts differentiate into distinct subsets in the presence of cytokines and cartilage. Arthritis Res. Ther. 18, 270 (2016).
68. Dakin S. G, et al. Persistence of tendon inflammation: a leading role for the stroma?. Proc. 4th Int. Scientif. Tendinopathy Symposium. http://webcms.uct.ac.za/.sites/default/files/image-tool/images/311/Documents/.ISTS%202016%20Programme%20booklet.pdf (2016
69. Kietrys D. M, et al. Aging contributes to inflammation in upper extremity tendons and declines in forelimb agility in a rat model of upper extremity overuse. PLoS ONE 7, e46954 (2012).
70. Pingel J, et al. Increased mast cell numbers in a calcaneal tendon overuse model. Scand. J. Med. Sci. Sports 23, e353-e360 (2013).
71. Mantovani A, Sica A, & Locati M. Macrophage polarization comes of age. Immunity 23, 344-346 (2005).
72. Mantovani A, Sozzani S, Locati M, Allavena P, & Sica A. Macrophage polarization: tumor-Associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23, 549-555 (2002).
73. Murray P. J, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41, 14-20 (2014).
74. Dakin S. G, et al. Macrophage sub-populations and the lipoxin A4 receptor implicate active inflammation during equine tendon repair. PLoS ONE 7, e32333 (2012).
75. Hackett L, Millar N. L, Lam P, & Murrell G. A. Are the symptoms of calcific tendinitis due to neoinnervation and/or neovascularization?. J. Bone Joint Surg. Am. 98, 186-192 (2016).
76. Matthews T. J, Hand G. C, Rees J. L, Athanasou N. A, & Carr A. J. Pathology of the torn rotator cuff tendon. Reduction in potential for repair as tear size increases. J. Bone Joint Surg. Br. 88, 489-495 (2006).
77. Behzad H, Sharma A, Mousavizadeh R, Lu A, & Scott A. Mast cells exert pro-inflammatory effects of relevance to the pathophyisology of tendinopathy. Arthritis Res. Ther. 15, R184 (2013).
78. Marsolais D, Cote C. H, & Frenette J. Neutrophils and macrophages accumulate sequentially following Achilles tendon injury. J. Orthop. Res. 19, 1203-1209 (2001).
79. Dean B. J, Gettings P, Dakin S. G, & Carr A. J. Are inflammatory cells increased in painful human tendinopathy?. A systematic review. Br. J. Sports Med. 50, 216-220 (2016).
80. Millar N. L, et al. Inflammation is present in early human tendinopathy. Am. J. Sports Med. 38, 2085-2091 (2010).
81. Kragsnaes M. S, et al. Stereological quantification of immune-competent cells in baseline biopsy specimens from achilles tendons: results from patients with chronic tendinopathy followed for more than 4 years. Am. J. Sports Med. 42, 2435-2445 (2014).
82. Schubert T. E, Weidler C, Lerch K, Hofstadter F, & Straub R. H. Achilles tendinosis is associated with sprouting of substance P positive nerve fibres. Ann. Rheum. Dis. 64, 1083-1086 (2005).
83. Lui P. P, Maffulli N, Rolf C, & Smith R. K. What are the validated animal models for tendinopathy?. Scand. J. Med. Sci. Sports 21, 3-17 (2011).
84. Archambault J, Tsuzaki M, Herzog W, & Banes A. J. Stretch and interleukin 1beta induce matrix metalloproteinases in rabbit tendon cells in vitro. J. Orthop. Res. 20, 36-39 (2002).
85. Tsuzaki M, et al. IL 1 beta induces COX2, MMP 1, -3 and -13, ADAMTS 4, IL 1 beta and IL 6 in human tendon cells. J. Orthop. Res. 21, 256-264 (2003).
86. Bauge C, Leclercq S, Conrozier T, & Boumediene K. TOL19 001 reduces inflammation and MMP expression in monolayer cultures of tendon cells. BMC Complement. Altern. Med. 15, 217 (2015).
87. Dakin S. G, et al. Proteomic analysis of tendon extracellular matrix reveals disease stage-specific fragmentation and differential cleavage of COMP (cartilage oligomeric matrix protein). J. Biol. Chem. 289, 4919-4927 (2014).
88. Schmitz J, et al. IL 33, an interleukin 1 like cytokine that signals via the IL 1 receptor-related protein ST2 and induces T helper type 2 associated cytokines. Immunity 23, 479-490 (2005).
89. Kakkar R, Hei H, Dobner S, & Lee R. T. Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J. Biol. Chem. 287, 6941-6948 (2012).
90. Liew F. Y, Pitman N. I, & McInnes I. B. Disease-Associated functions of IL 33: the new kid in the IL 1 family. Nat. Rev. Immunol. 10, 103-110 (2010).
91. Millar N. L, et al. MicroRNA29a regulates IL 33 mediated tissue remodelling in tendon disease. Nat. Commun. 6, 6774 (2015).
92. [No authors listed.] IL 1 receptor-like 1 (IL1RL1; ST2); IL 33 (NF HEV). SciBX http://dx.doi.org/10.1038/.scibx.2014.488 (2014).
93. Scheller J, & Rose-John S. Interleukin 6 and its receptor: from bench to bedside. Med. Microbiol. Immunol. 195, 173-183 (2006).
94. Legerlotz K, Jones E. R, Screen H. R, & Riley G. P. Increased expression of IL 6 family members in tendon pathology. Rheumatology (Oxford) 51, 1161-1165 (2012).
95. Lin T. W, Cardenas L, Glaser D. L, & Soslowsky L. J. Tendon healing in interleukin 4 and interleukin 6 knockout mice. J. Biomech. 39, 61-69 (2006).
96. Legerlotz K, Jones G. C, Screen H. R, & Riley G. P. Cyclic loading of tendon fascicles using a novel fatigue loading system increases interleukin 6 expression by tenocytes. Scand. J. Med. Sci. Sports 23, 31-37 (2013).
97. Jelinsky S. A, et al. Regulation of gene expression in human tendinopathy. BMC Musculoskelet. Disord. 12, 86 (2011).
98. Langberg H, Olesen J. L, Gemmer C, & Kjaer M. Substantial elevation of interleukin 6 concentration in peritendinous tissue, in contrast to muscle, following prolonged exercise in humans. J. Physiol. 542, 985-990 (2002).
99. Waugh C. M, et al. In vivo biological response to extracorporeal shockwave therapy in human tendinopathy. Eur. Cells Mater. 29, 268-280 (2015).
100. Pedersen B. K, Steensberg A, & Schjerling P. Muscle-derived interleukin 6: possible biological effects. J. Physiol. 536, 329-337 (2001).
101. Hosaka Y, Kirisawa R, Ueda H, Yamaguchi M, & Takehana K. Differences in tumor necrosis factor (TNF)alpha and TNF receptor 1 mediated intracellular signaling factors in normal, inflamed and scar-formed horse tendons. J. Vet. Med. Sci. 67, 985-991 (2005).
102. John T, et al. Effect of pro-inflammatory and immunoregulatory cytokines on human tenocytes. J. Orthop. Res. 28, 1071-1077 (2010).
103. de Mos M, et al. Tendon degeneration is not mediated by regulation of Toll-like receptors 2 and 4 in human tenocytes. J. Orthop. Res. 27, 1043-1047 (2009).
104. Gaida J. E, Alfredson H, Forsgren S, & Cook J. L. A pilot study on biomarkers for tendinopathy: lower levels of serum TNF-Alpha and other cytokines in females but not males with Achilles tendinopathy. BMC Sports Sci. Med. Rehabil. 8, 5 (2016).
105. Hershey G. K. IL 13 receptors and signaling pathways: an evolving web. J. Allergy Clin. Immunol. 111, 677-690 (2003).
106. Lin T. W, Cardenas L, & Soslowsky L. J. Tendon properties in interleukin 4 and interleukin 6 knockout mice. J. Biomech. 38, 99-105 (2005).
107. Courneya J. P, et al. Interleukins 4 and 13 modulate gene expression and promote proliferation of primary human tenocytes. Fibrogen. Tissue Repair 3, 9 (2010).
108. Nurieva R, et al. Essential autocrine regulation by IL 21 in the generation of inflammatory T cells. Nature 448, 480-483 (2007).
109. Spolski R, & Leonard W. J. Interleukin 21: a double-edged sword with therapeutic potential. Nat. Rev. Drug Discov. 13, 379-395 (2014).
110. Foster P. S, & Mattes J. IL 21 comes of age. Immunol. Cell Biol. 87, 359-360 (2009).
111. Campbell A. L, et al. IL 21 receptor expression in human tendinopathy. Mediators Inflamm. 2014, 481206 (2014).
112. Lubberts E. The IL 23-IL 17 axis in inflammatory arthritis. Nat. Rev. Rheumatol. 11, 415-429 (2015).
113. Lubberts E, et al. IL 1 independent role of IL 17 in synovial inflammation and joint destruction during collagen-induced arthritis. J. Immunol. 167, 1004-1013 (2001).
114. Millar N. L, et al. IL 17A mediates inflammatory and tissue remodelling events in early human tendinopathy. Sci. Rep. 6, 27149 (2016).
115. McInnes I. B, et al. Secukinumab, a human anti-interleukin 17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386, 1137-1146 (2015).
116. Mease P. J, et al. Ixekizumab, an interleukin 17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24 week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT P1. Ann. Rheum. Dis. 76, 79-87 (2016).
117. Marchand F, Perretti M, & McMahon S. B. Role of the immune system in chronic pain. Nat. Rev. Neurosci. 6, 521-532 (2005).
118. Basbaum A. I, Bautista D. M, Scherrer G, & Julius D. Cellular and molecular mechanisms of pain. Cell 139, 267-284 (2009).
119. Ohishi S, et al. Evidence for involvement of prostaglandin I2 as a major nociceptive mediator in acetic acid-induced writhing reaction: a study using IP receptor disrupted mice. Adv. Exp. Med. Biol. 469, 265-268 (1999).
120. Ferry S. T, Afshari H. M, Lee J. A, Dahners L. E, & Weinhold P. S. Effect of prostaglandin E2 injection on the structural properties of the rat patellar tendon. Sports Med. Arthrosc. Rehabil. Ther. Technol. 4, 2 (2012).
121. Jones E. R, Jones G. C, Legerlotz K, & Riley G. P. Cyclical strain modulates metalloprotease and matrix gene expression in human tenocytes via activation of TGFbeta. Biochim. Biophys. Acta 1833, 2596-2607 (2013).
122. Kidd B. L, & Urban L. A. Mechanisms of inflammatory pain. Br. J. Anaesth. 87, 3-11 (2001).
123. Molloy T. J, Kemp M. W, Wang Y, & Murrell G. A. Microarray analysis of the tendinopathic rat supraspinatus tendon: glutamate signaling and its potential role in tendon degeneration. J. Appl. Physiol. 101, 1702-1709 (2006).
124. Dean B. J, et al. Differences in glutamate receptors and inflammatory cell numbers are associated with the resolution of pain in human rotator cuff tendinopathy. Arthritis Res. Ther. 17, 176 (2015).
125. Palmer R. M, Ashton D. S, & Moncada S. Vascular endothelial cells synthesize nitric oxide from L arginine. Nature 333, 664-666 (1988).
126. Murrell G. A, et al. Modulation of tendon healing by nitric oxide. Inflamm. Res. 46, 19-27 (1997).
127. Szomor Z. L, et al. Differential expression of cytokines and nitric oxide synthase isoforms in human rotator cuff bursae. Ann. Rheum. Dis. 60, 431-432 (2001).
128. Lin J. H, et al. Temporal expression of nitric oxide synthase isoforms in healing Achilles tendon. J. Orthop. Res. 19, 136-142 (2001).
129. Lin J, Wang M. X, Wei A, Zhu W, & Murrell G. A. The cell specific temporal expression of nitric oxide synthase isoforms during achilles tendon healing. Inflamm. Res. 50, 515-522 (2001).
130. Murrell G. A. Oxygen free radicals and tendon healing. J. Shoulder Elbow Surg. 16 (5 SuppL), S208-S214 (2007).
131. Murrell G. A. Using nitric oxide to treat tendinopathy. Br. J. Sports Med. 41, 227-231 (2007).
132. Xia W, Szomor Z, Wang Y, & Murrell G. A. Nitric oxide enhances collagen synthesis in cultured human tendon cells. J. Orthop. Res. 24, 159-172 (2006).
133. Molloy T. J, de Bock C. E, Wang Y, & Murrell G. A. Gene expression changes in SNAP-stimulated and iNOS-Transfected tenocytes -expression of extracellular matrix genes and its implications for tendon-healing. J. Orthop. Res. 24, 1869-1882 (2006).
134. Serhan C. N, & Savill J. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6, 1191-1197 (2005).
135. Buckley C. D, Gilroy D. W, & Serhan C. N. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 40, 315-327 (2014).
136. Serhan C. N. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92-101 (2014).
137. Dakin S. G, et al. Inflamm-Aging and arachadonic acid metabolite differences with stage of tendon disease. PLoS ONE 7, e48978 (2012).
138. Dakin S. G, et al. Inflammation activation and resolution in human tendon disease. Sci. Transl. Med. 7, 311ra173 (2015).
139. Schett G, Elewaut D, McInnes I. B, Dayer J. M, & Neurath M. F. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat. Med. 19, 822-824 (2013).
140. Andia I, Rubio-Azpeitia E, & Maffulli N. Platelet-rich plasma modulates the secretion of inflammatory/.angiogenic proteins by inflamed tenocytes. Clin. Orthop. Relat. Res. 473, 1624-1634 (2015).
141. Young M. Stem cell applications in tendon disorders: a clinical perspective. Stem Cells Int. 2012, 637836 (2012).
142. de la Durantaye M, Piette A. B, van Rooijen N, & Frenette J. Macrophage depletion reduces cell proliferation and extracellular matrix accumulation but increases the ultimate tensile strength of injured Achilles tendons. J. Orthop. Res. 32, 279-285 (2014).
143. Mounier R, et al. AMPKα1 regulates macrophage skewing at the time of resolution of inflammation during skeletal muscle regeneration. Cell. Metab. 18, 251-264 (2013).
144. Manning C. N, et al. Adipose-derived mesenchymal stromal cells modulate tendon fibroblast responses to macrophage-induced inflammation in vitro. Stem Cell Res. Ther. 6, 74 (2015).
145. Scott A, et al. Tenocyte responses to mechanical loading in vivo: a role for local insulin-like growth factor 1 signaling in early tendinosis in rats. Arthritis Rheum. 56, 871-881 (2007).
146. Schwartz A. J, et al. p38 MAPK signaling in postnatal tendon growth and remodeling. PLoS ONE 10, e0120044 (2015).
147. Poulsen R. C, Carr A. J, & Hulley P. A. Protection against glucocorticoid-induced damage in human tenocytes by modulation of ERK, Akt, and forkhead signaling. Endocrinology 152, 503-514 (2011).
148. Millar N. L, et al. Hypoxia: a critical regulator of early human tendinopathy. Ann. Rheum. Dis. 71, 302-310 (2012).
149. Busch F, Mobasheri A, Shayan P, Stahlmann R, & Shakibaei M. Sirt 1 is required for the inhibition of apoptosis and inflammatory responses in human tenocytes. J. Biol. Chem. 287, 25770-25781 (2012).
150. Buhrmann C, et al. Curcumin modulates nuclear factor ?B (NF ?B)-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3 kinase/Akt pathway. J. Biol. Chem. 286, 28556-28566 (2011).
151. McInnes I. B, & O?Dell J. R. State of the-Art: rheumatoid arthritis. Ann. Rheum. Dis. 69, 1898-1906 (2010).
152. Genovese M. C. Inhibition of p38: has the fat lady sung?. Arthritis Rheum. 60, 317-320 (2009).
153. Boyle D. L, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann. Rheum. Dis. 74, 1311-1316 (2015).
154. Berkoff D. J, Kallianos S. A, Eskildsen S. M, & Weinhold P. S. Use of an IL1 receptor antagonist to prevent the progression of tendinopathy in a rat model. J. Orthop. Res. 34, 616-622 (2016).
155. Ma Y, Yan X, Zhao H, & Wang W. Effects of interleukin 1 receptor antagonist on collagen and matrix metalloproteinases in stress-shielded achilles tendons of rats. Orthopedics 35, e1238-e1244 (2012).
156. Fredberg U, & Ostgaard R. Effect of ultrasound-guided, peritendinous injections of adalimumab and anakinra in chronic Achilles tendinopathy: a pilot study. Scand. J. Med. Sci. Sports 19, 338-344 (2009).
157. Andersen M. B, Pingel J, Kjaer M, & Langberg H. Interleukin 6: a growth factor stimulating collagen synthesis in human tendon. J. Appl. Physiol. (1985) 110, 1549-1554 (2011).
158. Gilroy D. W, Lawrence T, Perretti M, & Rossi A. G. Inflammatory resolution: new opportunities for drug discovery. Nat. Rev. Drug Discov. 3, 401-416 (2004).
159. Bushati N, & Cohen S. M. microRNA functions. Annu. Rev. Cell Dev. Biol. 23, 175-205 (2007).
160. Bartel D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233 (2009).
161. Zeng L, et al. MicroRNA 210 overexpression induces angiogenesis and neurogenesis in the normal adult mouse brain. Gene Ther. 21, 37-43 (2014).
162. Usman M. A, et al. The effect of administration of double stranded microRNA 210 on acceleration of Achilles tendon healing in a rat model. J. Orthop. Sci. 20, 538-546 (2015).
163. Chen C. H, et al. Effectiveness of microRNA in down-regulation of TGF-β gene expression in digital flexor tendons of chickens: in vitro and in vivo study. J. Hand Surg. Am. 34, 1777-1784.e1 (2009).
164. Chen Q, Lu H, & Yang H. Chitosan inhibits fibroblasts growth in Achilles tendon via TGF β1/.Smad3 pathway by miR 29b. Int. J. Clin. Exp. Pathol. 7, 8462-8470 (2014).